Canaccord Genuity set a $73.00 price target on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) in a research note released on Thursday morning. The brokerage currently has a buy rating on the stock.

AERI has been the topic of a number of other reports. Mizuho reissued a buy rating and issued a $70.00 price objective on shares of Aerie Pharmaceuticals in a research note on Wednesday, October 25th. Zacks Investment Research raised Aerie Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, October 24th. Needham & Company LLC reissued a buy rating and issued a $65.00 price objective on shares of Aerie Pharmaceuticals in a research note on Sunday, September 17th. Stifel Nicolaus reissued a buy rating and issued a $70.00 price objective on shares of Aerie Pharmaceuticals in a research note on Friday, July 28th. Finally, Cantor Fitzgerald reissued a buy rating and issued a $62.00 price objective on shares of Aerie Pharmaceuticals in a research note on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the company. Aerie Pharmaceuticals has an average rating of Buy and a consensus target price of $71.43.

Aerie Pharmaceuticals (NASDAQ:AERI) traded down $1.00 on Thursday, hitting $58.70. The stock had a trading volume of 378,123 shares, compared to its average volume of 432,440. Aerie Pharmaceuticals has a 52 week low of $35.20 and a 52 week high of $66.25. The company has a debt-to-equity ratio of 0.78, a current ratio of 15.24 and a quick ratio of 15.24.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/canaccord-genuity-analysts-give-aerie-pharmaceuticals-inc-aeri-a-73-00-price-target/1713995.html.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AERI. Ameritas Investment Partners Inc. grew its holdings in Aerie Pharmaceuticals by 11.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock valued at $140,000 after buying an additional 275 shares during the last quarter. Quantbot Technologies LP grew its holdings in Aerie Pharmaceuticals by 792.5% in the 3rd quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock valued at $144,000 after buying an additional 2,647 shares during the last quarter. BNP Paribas Arbitrage SA grew its holdings in Aerie Pharmaceuticals by 2,711.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock valued at $195,000 after buying an additional 3,579 shares during the last quarter. Amalgamated Bank acquired a new stake in Aerie Pharmaceuticals in the 2nd quarter valued at approximately $204,000. Finally, Great West Life Assurance Co. Can grew its holdings in Aerie Pharmaceuticals by 65.0% in the 3rd quarter. Great West Life Assurance Co. Can now owns 4,160 shares of the company’s stock valued at $204,000 after buying an additional 1,639 shares during the last quarter. 95.71% of the stock is currently owned by hedge funds and other institutional investors.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.